SCFAs, particularly butyrate, have immunomodulatory properties that can influence anti-tumor responses by regulating the levels of immune-suppressing Tregs and tumor-killing CD4 + and CD8 + T cells [54]. This evidence concerns the gene CD8A and neoplasm.